PREVENTION OF EMESIS IN PATIENTS RECEIVING CYTOTOXIC DRUGS BY GR38032F, A SELECTIVE 5-HT3 RECEPTOR ANTAGONIST
- 1 June 1987
- journal article
- research article
- Published by Elsevier in The Lancet
- Vol. 329 (8548), 1461-1463
- https://doi.org/10.1016/s0140-6736(87)92208-2
Abstract
No abstract availableThis publication has 10 references indexed in Scilit:
- FIRST RESULTS WITH ICS 205-930 (5-HT3 RECEPTOR ANTAGONIST) IN PREVENTION OF CHEMOTHERAPY-INDUCED EMESISThe Lancet, 1987
- 5-hydroxytryptamine m-receptor antagonism to prevent cisplatin-induced emesisNeuropharmacology, 1986
- Inhibition of cisplatin‐induced vomiting by selective 5‐hydroxytryptamine M‐receptor antagonismBritish Journal of Pharmacology, 1986
- Nabilone and prochlorperazine: a useful combination for emesis induced by cytotoxic drugs.BMJ, 1985
- Identification of serotonin M-receptor subtypes and their specific blockade by a new class of drugsNature, 1985
- Randomised trial of intravenous high dose metoclopramide and intramuscular chlorpromazine in controlling nausea and vomiting induced by cytotoxic drugs.BMJ, 1985
- Neuronal 5-HT receptors in the peripheryNeuropharmacology, 1984
- Advances in anti-emetic therapyCancer Treatment Reviews, 1984
- MetoclopramideGastroenterology, 1979
- Blockade of neuronal tryptamine receptors by metoclopramideEuropean Journal of Pharmacology, 1978